Innate Pharma S.A. (IPHA)

FR — Healthcare Sector
Peers: ELYM  HCWB  INBX  ANEB  PRDS  STTK  CSBR  IPSC  ADXN  APM  CYAD  DYAI  MOLN  MNOV  CYT 

Automate Your Wheel Strategy on IPHA

With Tiblio's Option Bot, you can configure your own wheel strategy including IPHA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IPHA
  • Rev/Share 0.1557
  • Book/Share 0.109
  • PB 17.2954
  • Debt/Equity 3.5086
  • CurrentRatio 2.5997
  • ROIC -0.5943

 

  • MktCap 173722437.0336
  • FreeCF/Share -0.0899
  • PFCF -23.84
  • PE -3.0884
  • Debt/Assets 0.2791
  • DivYield 0
  • ROE -2.6293

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
IPHA
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncol.

Read More
image for news Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Outcome of Innate Pharma's 2025 Annual General Meeting
IPHA
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.

Read More
image for news Outcome of Innate Pharma's 2025 Annual General Meeting
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
IPHA
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical developmen.

Read More
image for news Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
IPHA
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.

Read More
image for news Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma announces conference call and webcast for Q1 2025 business update
IPHA
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.

Read More
image for news Innate Pharma announces conference call and webcast for Q1 2025 business update
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
IPHA
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the fil.

Read More
image for news Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
IPHA
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload,.

Read More
image for news Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
IPHA
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

Read More
image for news Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Innate Pharma: Moving Into The Padcev Space
IPHA
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Positive

Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential. Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.

Read More
image for news Innate Pharma: Moving Into The Padcev Space
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
IPHA
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.

Read More
image for news Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
IPHA
Published: February 17, 2025 by: Business Wire
Sentiment: Neutral

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

Read More
image for news Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

About Innate Pharma S.A. (IPHA)

  • IPO Date 2019-10-17
  • Website https://www.innate-pharma.com
  • Industry Biotechnology
  • CEO Mr. Jonathan E. Dickinson B.Sc., M.B.A.
  • Employees 181

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.